BR112021020257A2 - Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico - Google Patents

Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico

Info

Publication number
BR112021020257A2
BR112021020257A2 BR112021020257A BR112021020257A BR112021020257A2 BR 112021020257 A2 BR112021020257 A2 BR 112021020257A2 BR 112021020257 A BR112021020257 A BR 112021020257A BR 112021020257 A BR112021020257 A BR 112021020257A BR 112021020257 A2 BR112021020257 A2 BR 112021020257A2
Authority
BR
Brazil
Prior art keywords
amorphous solid
formulations
plasma concentrations
compound
achieve therapeutic
Prior art date
Application number
BR112021020257A
Other languages
English (en)
Portuguese (pt)
Inventor
Ajay Saxena
Singh Chowan Gajendra
Kalani Levons Jaquan
Poorna Reddy Jay
J Stefanski Kevin
Swamy Panduranga Narayan
J Garmise Robert
Roopa Narasimhamurthy
Shabeerali Pattasseri
Sharmistha Pal
Koravady Sridhar Srikanth
M Ziemba Theresa
M Waknis Vrushali
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112021020257A2 publication Critical patent/BR112021020257A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112021020257A 2019-04-11 2020-04-10 Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico BR112021020257A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11
PCT/US2020/027677 WO2020210629A1 (en) 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Publications (1)

Publication Number Publication Date
BR112021020257A2 true BR112021020257A2 (pt) 2021-12-07

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020257A BR112021020257A2 (pt) 2019-04-11 2020-04-10 Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico

Country Status (18)

Country Link
US (2) US12509461B2 (https=)
EP (1) EP3953355A1 (https=)
JP (2) JP2022526656A (https=)
KR (1) KR20210151183A (https=)
CN (1) CN113924300A (https=)
AR (1) AR118650A1 (https=)
AU (2) AU2020271103B2 (https=)
BR (1) BR112021020257A2 (https=)
CA (1) CA3132530A1 (https=)
CL (1) CL2021002627A1 (https=)
CO (1) CO2021015054A2 (https=)
EA (1) EA202192753A1 (https=)
IL (1) IL287103A (https=)
MX (2) MX2021012288A (https=)
PE (1) PE20212367A1 (https=)
SG (1) SG11202111131VA (https=)
TW (1) TW202104228A (https=)
WO (1) WO2020210629A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212644A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
IL310894A (en) 2021-09-17 2024-04-01 Bristol Myers Squibb Co Milovacian for the prevention and treatment of thromboembolic disorders
MA71692A (fr) 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
KR20250136432A (ko) 2023-02-06 2025-09-16 브리스톨-마이어스 스큅 컴퍼니 밀벡시안 제약 조성물
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2025220042A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising asundexian and use thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83812B (en) 1985-11-27 1988-03-15 Syntex Inc Process for preparing amorphous benzimidazole derivatives
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
CN1402629A (zh) * 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
MY172424A (en) * 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
NO2721243T3 (https=) 2014-10-01 2018-10-20
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
ES2791319T3 (es) 2016-04-22 2020-11-03 Astrazeneca Ab Inhibidores de MCL1 macrocíclicos para tratar el cáncer

Also Published As

Publication number Publication date
AU2020271103A1 (en) 2021-12-02
AR118650A1 (es) 2021-10-20
WO2020210629A1 (en) 2020-10-15
EA202192753A1 (ru) 2022-01-11
TW202104228A (zh) 2021-02-01
AU2020271103B2 (en) 2026-01-08
MX2021012288A (es) 2021-11-12
IL287103A (en) 2021-12-01
AU2025279715A1 (en) 2026-01-15
MX2025011559A (es) 2025-11-03
JP2025131625A (ja) 2025-09-09
CN113924300A (zh) 2022-01-11
CA3132530A1 (en) 2020-10-15
US20260042761A1 (en) 2026-02-12
US20220144835A1 (en) 2022-05-12
CL2021002627A1 (es) 2022-05-06
EP3953355A1 (en) 2022-02-16
US12509461B2 (en) 2025-12-30
JP2022526656A (ja) 2022-05-25
CO2021015054A2 (es) 2021-11-19
SG11202111131VA (en) 2021-11-29
PE20212367A1 (es) 2021-12-21
KR20210151183A (ko) 2021-12-13

Similar Documents

Publication Publication Date Title
BR112021020257A2 (pt) Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
BRPI0510327A (pt) composições e métodos terapêuticos antimicrobianos
BR112021006392A2 (pt) moduladores da alfa-1 antitripsina
EP4252848A3 (en) Oxysterols and methods of use thereof
BR112019016497A2 (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer.
CU20190045A7 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas que son inhibidores de la dihidroorotato deshidrogenasa (dhodh) útiles para el tratamiento o prevención de trastornos hiperproliferativos e inflamatorios
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
BR112015009806A2 (pt) composições adjuvantes aquosas
JOP20170107B1 (ar) مشتقات سلفوناميد عطرية
EP4609866A3 (en) Oxysterols and methods of use thereof
BR112015024770B8 (pt) formulação biocida e método para tratamento de água
BR112015008847A2 (pt) composições compreendendo ácido peróxido
BR112012025390A2 (pt) composto de tetraidrobenzotiofeno
BR112015014089A2 (pt) composições pesticidas e processos relacionados às mesmas
BR112015023658A2 (pt) formulação de vitamina d de liberação modificada, estabilizada e método de administração desta
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
TN2011000659A1 (fr) Formulation pharmaceutique
EP4316591A3 (en) Oxysterols and methods of use thereof
BR112012023942A2 (pt) curativo para feridas e processo para a preparação de um curativo para feridas.
EP4599887A8 (en) Oxysterols and methods of use thereof
BR112018014794A2 (pt) pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
BR112013017302A2 (pt) formulações de imunossupressor
UY37705A (es) Nuevos derivados de pirazol bicíclicos
PH12021551339A1 (en) Insulin conjugates

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]